Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
And, you still idolize the CEO….
There is a reason for that…
Bob, I expect you are on to something….
“I’d rather lose everything then sell at these levels”
I’ve never understood this logic.
This appears to be septic
That maybe a stretch..
Crypto is really breaking down hard now, so let’s see where this takes us next…
avoid e-wallets and buy gold….
Jess, SRNE completely collapsed.. 52 week low. I researched this two years ago. They have nothing..
Complete collapse.. 52 week low
https://stocktwits.com/James_Bond/message/413249382
Don’t be so negative. Spring is only 120 days away!
Our high today is forecasted to be 77 degrees..
Jess, SRNE should be avoided at all costs..
This rumor looks legit. Sold..
I laughed so hard I cried. A glimpse of Jess..
https://twitter.com/dev_jonatan/status/1465360618199056385?s=21
$AUPH dropped from $28 to $18 last two weeks
— Kevin Wolcott (@Kevin_W81) November 29, 2021
One trick pony, Jess.
They vomited up the stock today..
Variant is trumps data..
Omicron- So many shots from the hip. -Disturbing.
Being destroyed like the micro cap biotechs… puzzling..
96 cents
Jess, for FSGS, Aurinia decided to discontinue the trial as they could not recruit the number of patients that they needed, in the time constraints of the trial..
Jess, we need to clarify your post. The DES & FSGS Aurinia trials failed as they did not meet their end points. Aurinia stated there would be no further work by them on these two compounds..
As you may remember, I owned Scampo when it was acquired and was enthusiastic when Peter came on board because he is known as a serial seller.
$18.40?? Biotechs in general are getting whacked
This SA article is a very good review of the LN space. There are 5 compounds under review.
Also, some color on the Aurina FGS trial.
Aurinia Pharmaceuticals: Potential Blockbuster Justifies Big Pharma M&A Interest https://seekingalpha.com/article/4471261-aurinia-auph-stock-big-pharma-buyout-interest?source=copyToPasteboard
This analyst is holding out for $15. That just isn’t going to happen. No way..
Aurinia Pharmaceuticals: Potential Blockbuster Justifies Big Pharma M&A Interest https://seekingalpha.com/article/4471261-aurinia-auph-stock-big-pharma-buyout-interest?source=copyToPasteboard
A reminder: Lupkynis is just as effective today as it was last week!!!!!
Very true…
Got a buy order in at $19.70. Wish me luck. This is like an old friend like the Glickster…
Adam weighs in:
$AUPH didn’t just file a mixed shelf on Friday, it also entered into a $250M ATM stock sale agreement with Cantor Fitzgerald.
— Adam Feuerstein ✡️ (@adamfeuerstein) November 22, 2021
The buyout speculation looks well past its expiration date.
From $34 to $23 in less than 30 days. Bounce??
Splat, I mean zzaatt, this is one of your best posts of all time..
The CEO of Endra has all his wealth tied up in Rolex watches. That’s what he does..
If the buyout was offered, it would have to be disclosed as that is material information..
Comments: “ A poster on StockTwits suggested that AUPH had to refile their old shelf since they no longer qualified as a foreign issuer.”
If this were the case, this fact would have needed to be filed with the filing..
Rum, totally agree with your assessment.. They got no offers that they could accept. Peter principle..
“It’s undervalued at this price. The world of micros is so much fun. Scoop away at any price just like TMDI.
The odds are it will be over 5 this time next year and possibly bought out in 2023 by GE.”
GE is not interested..
No BMY buyout.. They are going to slog it out I suppose..
Virtual Conference is Nov 30- Dec 2. Fireside chat is Nov 22???
Press Release Details
Revance to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference
November 18, 2021
PDF Version
NASHVILLE, Tenn.--(BUSINESS WIRE)--Nov. 18, 2021-- Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that the company’s Chief Executive Officer, Mark Foley, and Chief Financial Officer, Tobin Schilke, will participate in a fireside chat at the Piper Sandler 33rd Annual Virtual Healthcare Conference.
The fireside chat will be available online beginning November 22 in the investor relations section of the company’s website at www.revance.com. The virtual conference will be held from November 30 through December 2, 2021.